Magnetic Nanoparticle T Cell Activation via Local Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer and autoimmune disease treatments are non-specific, leading to significant side effects and morbidities, as they often induce non-targeted cell death and fail to reactivate dysfunctional immune cells within tumor microenvironments, necessitating a more targeted approach to activate T cells for immune response re-ignition.
Innovation Solution
A method involving the use of magnetic nanoparticles functionalized with T cell receptor binding moieties, which are exposed to a magnetic field to apply mechanical force and activate T cells, thereby re-establishing anti-tumor immunity and controlling T cell phenotype and action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-specific cancer treatments (chemotherapy, surgery) are used, then tumor tissue is eliminated, but healthy immune cells within the tumor microenvironment are damaged and side effects occur
Solution Approach 1:
The patent applies local quality by functionalizing magnetic nanoparticles with specific T cell receptor binding moieties that recognize and bind only to T cells within the tumor microenvironment. This enables selective targeting of dysfunctional T cells for reactivation while leaving other cells unaffected, thereby eliminating side effects while maintaining treatment effectiveness through localized immune system reactivation.
2Object-affected harmful factors
If non-specific immune suppression treatments are used for autoimmune diseases, then immune response is reduced, but infection risk and malignant disease risk increase
Solution Approach 1:
The patent enables precise local quality control by using TCR-binding magnetic nanoparticles that specifically target and modulate T cell activity. This allows selective reactivation of dysfunctional T cells in tumor microenvironments or specific immune compartments without broadly suppressing the entire immune system, thereby maintaining protective immune functions while treating autoimmune conditions.
3Reliability
If hyperthermia treatment is used, then tumor cell death is induced, but T cell reactivation is not achieved
Solution Approach 1:
The patent introduces magnetic nanoparticles functionalized with TCR binding moieties as an intermediary between the magnetic field and T cells. These nanoparticles bind specifically to T cell receptors and transmit mechanical forces from the magnetic field to the T cells, directly activating them through force-induced conformational changes. This intermediary mechanism enables T cell reactivation without relying on hyperthermia, providing a targeted approach that hyperthermia alone cannot achieve.
Solution Approach 2:
The patent replaces the thermal mechanical system (hyperthermia) with a direct mechanical force system. Instead of using heat to induce cell death, the invention applies controlled mechanical forces via magnetic nanoparticles to directly activate T cell receptors. This substitution of mechanical action for thermal action enables selective T cell reactivation while avoiding the non-specific cell death caused by hyperthermia.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted T cell activation, reducing side effects by selectively reactivating T cells within tumor microenvironments and enhancing immune responses, potentially leading to improved treatment outcomes for cancer and autoimmune diseases.
Implementation Method 1
The MNPs may be any size suitable for in vivo or ex vivo administration and are capable of binding to the TCR binding moiety. The MNPs may be subjected to a magnetic field in order to apply a force to the TCR of a T cell via a bound MNP
Implementation Method 2
In any of the methods of the invention, preferably the magnetic field is an oscillating magnetic field. The oscillating magnetic field applies a force to the TCR of a T cell via a bound MNP (which binds to the TCR by virtue of the TCR binding moiety), thereby activating the T cell.
Data Source
AI summary
Provided is a method of activating T cells, the method including contacting the T cells with a plurality of magnetic nanoparticles (MNPs), wherein each MNP is functionalized with a T cell receptor (TCR) binding moiety, and exposing the T cells to a magnetic field. The method finds utility in the treatment of cancer and autoimmune disease.